The EU has issued new draft guidelines on stability testing required
to support a variation to a Marketing Authorization. Under the new
rules, additional data must be submitted to accompany major, Type II
variations, such as a change in batch size or switching suppliers. The
draft document is posted on the European Medicines Agency (EMA) website.